TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Validation of a Novel Paradigm for Screening Medications for Nicotine Dependence
Brief Summary: The goal of the proposed study is to validate an experimental paradigm to assess medication effects on smoking relapse following a brief (3-day) monitored period of smoking abstinence and a programmed cigarette lapse.


Options:
A: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: sustained-release bupropion (Zyban(R)); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Psychodynamic Model Training (R) = PDM(R); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Validation of a Novel Paradigm for Screening Medications for Nicotine Dependence
Brief Summary: The goal of the proposed study is to validate an experimental paradigm to assess medication effects on smoking relapse following a brief (3-day) monitored period of smoking abstinence and a programmed cigarette lapse.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Varenicline and Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline and Placebo Patch | Arm Label: Varenicline and Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Nicotine Patch | Intervention Type: DRUG; Name: Varenicline, Nicotine Patch; Assigned to Arm(s): Varenicline and Nicotine Patch | Intervention Type: DRUG; Name: Varenicline and Placebo Patch; Assigned to Arm(s): Varenicline and Placebo Patch
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline
D: Arm Label: Champix; Type: EXPERIMENTAL; Interventions: Drug: Champix | Arm Label: Long & Combination patch treatment; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicoderm patch combined with gum or inhaler | Arm Label: Standard patch treatment; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicoderm patch | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Champix | Intervention Type: DRUG; Name: Transdermal Nicoderm patch combined with gum or inhaler; Assigned to Arm(s): Long & Combination patch treatment | Intervention Type: DRUG; Name: Transdermal Nicoderm patch; Assigned to Arm(s): Standard patch treatment

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Validation of a Novel Paradigm for Screening Medications for Nicotine Dependence
Brief Summary: The goal of the proposed study is to validate an experimental paradigm to assess medication effects on smoking relapse following a brief (3-day) monitored period of smoking abstinence and a programmed cigarette lapse.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline
B: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Selegiline + nicotine replacement therapy | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo + nicotine replacement therapy | Intervention Type: DRUG; Name: Selegiline + nicotine replacement therapy; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo + nicotine replacement therapy; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Validation of a Novel Paradigm for Screening Medications for Nicotine Dependence
Brief Summary: The goal of the proposed study is to validate an experimental paradigm to assess medication effects on smoking relapse following a brief (3-day) monitored period of smoking abstinence and a programmed cigarette lapse.


Options:
A: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline (CP-526,555) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo Arm | Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): Treatment Arm
B: Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline tartrate | Arm Label: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Nicotine Replacement Therapy Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Replacement Therapy Patch | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline tartrate; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: Nicotine Replacement Therapy Patch; Assigned to Arm(s): Nicotine Replacement Therapy Patch
C: Arm Label: study groups; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): study groups | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): control group
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I/II, Open-Label, Dose-Escalation Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
Brief Summary: The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.


Options:
A: Arm Label: 1 Catumaxomab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Catumaxomab (Removab), Procedure: paracentesis | Arm Label: 2:; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Catumaxomab (Removab); Assigned to Arm(s): 1 Catumaxomab | Intervention Type: PROCEDURE; Name: paracentesis; Assigned to Arm(s): 1 Catumaxomab
B: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: NY-ESO-1 OLP4 | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: NY-ESO-1 OLP4 + Montanide | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: NY-ESO-1 OLP4 + Montanide + Poly-ICLC | Intervention Type: BIOLOGICAL; Name: NY-ESO-1 OLP4; Assigned to Arm(s): Cohort 1 | Intervention Type: BIOLOGICAL; Name: NY-ESO-1 OLP4 + Montanide; Assigned to Arm(s): Cohort 2 | Intervention Type: BIOLOGICAL; Name: NY-ESO-1 OLP4 + Montanide + Poly-ICLC; Assigned to Arm(s): Cohort 3
C: Intervention Type: BIOLOGICAL; Name: CDX-1401 in combination with Resiquimod and/or Poly-ICLC; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: CDX-1401; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Resiquimod; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: poly-ICLC; Assigned to Arm(s): N/A
D: Arm Label: Abagovomab; Type: EXPERIMENTAL; Interventions: Biological: Abagovomab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Abagovomab; Assigned to Arm(s): Abagovomab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Assess the Role of Oral Sucrose in Reducing the Pain to Orogastric Tube Insertion in Preterm Neonates
Brief Summary: RESEARCH HYPOTHESIS Orally administered sucrose 2 minutes prior to the procedure of OGT insertion reduces pain associated with the procedure.

AIMS AND OBJECTIVES:

To study the effect of 24% oral sucrose on decreasing the painful response to orogastric tube insertion .


Options:
A: Arm Label: Sucrose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sucrose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double distilled water | Intervention Type: DRUG; Name: Sucrose; Assigned to Arm(s): Sucrose | Intervention Type: DRUG; Name: Double distilled water; Assigned to Arm(s): Placebo
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: N2O | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: oxygen | Intervention Type: OTHER; Name: N2O; Assigned to Arm(s): A | Intervention Type: OTHER; Name: oxygen; Assigned to Arm(s): B
C: Arm Label: sucrose; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: supplemental breast milk; Type: ACTIVE_COMPARATOR; Interventions: Other: supplemental breast milk | Arm Label: Breast feeding; Type: ACTIVE_COMPARATOR; Interventions: Other: breast feeding | Intervention Type: OTHER; Name: breast feeding; Assigned to Arm(s): Breast feeding | Intervention Type: OTHER; Name: supplemental breast milk; Assigned to Arm(s): supplemental breast milk | Intervention Type: OTHER; Name: sucrose; Assigned to Arm(s): sucrose
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 25% Sucrose | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: facilitated tucking | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sucrose and facilitated tucking | Intervention Type: PROCEDURE; Name: 25% Sucrose; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: facilitated tucking; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Sucrose and facilitated tucking; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study
Brief Summary: The study is designed to determine the long term, post trial effects of the two interventions studied in ADVANCE (routine blood pressure lowering with perindopril-indapamide as compared with placebo and intensive gliclazide-MR based glucose control as compared to standard guideline based glucose control) in individuals with type 2 diabetes at high risk of cardiovascular events. The long term, post randomization effects of the two study interventions will be investigated separately as they were for the main trial. This study will clarify and quantify the long-term, post trial (often referred to as legacy) effects of these two interventions in a broader population of patients with type 2 diabetes from high and low to middle income countries, and in the setting of comprehensive cardiovascular risk factor treatment. With the ADVANCE trial infrastructure and surveillance system already in place, the implementation of extended follow-up will be feasible. The conclusions of this follow up study will have profound clinical implications for the care of patients with type 2 diabetes around the world.


Options:
A: Arm Label: Saxagliptin; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: N/A
C: Arm Label: linagliptin 5mg; Type: EXPERIMENTAL; Interventions: Drug: Linagliptin 5mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Linagliptin 5mg; Assigned to Arm(s): linagliptin 5mg
D: Arm Label: BI 10773 low dose; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: BI 10773 | Arm Label: BI 10773 high dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Superiority of Insulin Glargine Lantus vs. NPH: Treat to Normoglycemia Concept.Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-nave People With Type 2 Diabetes Mellitus Treated With at Least One OAD and Not Adequately Controlled
Brief Summary: Primary Objective:

To demonstrate the superiority of insulin glargine over insulin NPH (Neutral Protamin Hagedornon) the change in HbA1c from baseline to the end of the treatment period.

Secondary Objective:

To compare between treatment groups:

* Plasma glucose (fasting, nocturnal) over time,
* Changes from baseline in HbA1c over time,
* Percentage of patients who reach the target of HbA1c \<7 and \<6.5,
* Use of prandial insulin as rescue medication at month 6,
* Incidence and rate of hypoglycemia (symptomatic diurnal and nocturnal, asymptomatic and severe),
* Daily dose of insulin,
* Change in body weight from baseline,
* Evolution of 8-point plasma-glucose (PG) profiles,
* Overall safety,
* Patient reported outcomes (treatment satisfaction).


Options:
A: Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine (HOE901) [Lantus], Drug: Glimepiride | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: human insulin [NPH] | Intervention Type: DRUG; Name: Insulin Glargine (HOE901) [Lantus]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: human insulin [NPH]; Assigned to Arm(s): 2
C: Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (U300) | Arm Label: "Standard of care" commercially available basal insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine (U100), Drug: NPH insulin, Drug: insulin detemir, Drug: insulin degludec | Intervention Type: DRUG; Name: insulin glargine (U300); Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: insulin glargine (U100); Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): "Standard of care" commercially available basal insulin
D: Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Hidradenitis Suppirativa With Etanercept Injection
Brief Summary: Therapy with etanercept, a TNF inhibitor will reverse the inflammation, symptoms and quality of life and allow healing of HS.


Options:
A: Intervention Type: PROCEDURE; Name: Long-pulsed Nd:YAG laser 1064 nm; Assigned to Arm(s): N/A
B: Arm Label: Adalimumab 40 mg qwk; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 40 mg eow, Adalimumab 40 mg qwk | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: infliximab; Type: EXPERIMENTAL; Interventions: Drug: infliximab, Drug: Placebo Comparator | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): infliximab | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): Placebo, infliximab
D: Arm Label: placebo controlled; Type: N/A; Interventions: Drug: etanercept | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): placebo controlled

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Wiser Choices In Osteoporosis Choice II
Brief Summary: Emphasis in treating osteoporosis has been on T-scores rather than overall fracture risk. Fracture Risk Assessment Tool (FRAX) supports a risk sensitive approach to osteoporosis treatment by providing an absolute fracture risk. FRAX combined with a decision aid may promote a shared decision making approach with patients, allowing the clinician and patient to weigh potential fracture risk (without treatment), versus risk reduction with medication (including side effects and costs). OSTEOPOROSIS CHOICE II will test the effectiveness of:

* FRAX
* FRAX + decision aid
* Usual care (no decision aid and no FRAX given to clinician)


Options:
A: Arm Label: 1 Patient decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: 1 Patient decision aid, Behavioral: 2 Usual care | Arm Label: 2 Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 2 Usual care | Intervention Type: BEHAVIORAL; Name: 1 Patient decision aid; Assigned to Arm(s): 1 Patient decision aid | Intervention Type: BEHAVIORAL; Name: 2 Usual care; Assigned to Arm(s): 1 Patient decision aid, 2 Usual care
B: Arm Label: Decision Aid Tool; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Aid Tool | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Other: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Decision Aid Tool; Assigned to Arm(s): Decision Aid Tool | Intervention Type: OTHER; Name: Treatment as Usual; Assigned to Arm(s): Control
C: Arm Label: Care coordinator + Decision Support Software; Type: EXPERIMENTAL; Interventions: Other: Care Coordinator + Decision Support Software | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Care Coordinator + Decision Support Software; Assigned to Arm(s): Care coordinator + Decision Support Software | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
D: Arm Label: FRAX + Decision Aid; Type: EXPERIMENTAL; Interventions: Behavioral: FRAX + Decision Aid | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: FRAX estimated fracture risk; Type: EXPERIMENTAL; Interventions: Behavioral: FRAX estimated fracture risk | Intervention Type: BEHAVIORAL; Name: FRAX + Decision Aid; Assigned to Arm(s): FRAX + Decision Aid | Intervention Type: BEHAVIORAL; Name: FRAX estimated fracture risk; Assigned to Arm(s): FRAX estimated fracture risk

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Wiser Choices In Osteoporosis Choice II
Brief Summary: Emphasis in treating osteoporosis has been on T-scores rather than overall fracture risk. Fracture Risk Assessment Tool (FRAX) supports a risk sensitive approach to osteoporosis treatment by providing an absolute fracture risk. FRAX combined with a decision aid may promote a shared decision making approach with patients, allowing the clinician and patient to weigh potential fracture risk (without treatment), versus risk reduction with medication (including side effects and costs). OSTEOPOROSIS CHOICE II will test the effectiveness of:

* FRAX
* FRAX + decision aid
* Usual care (no decision aid and no FRAX given to clinician)


Options:
A: Arm Label: One-on-one counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle and medication intervention | Arm Label: Web counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle and medication intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle and medication intervention; Assigned to Arm(s): One-on-one counseling, Web counseling
B: Arm Label: Counseling; Type: NO_INTERVENTION; Interventions: Other: counseling intervention, Other: CD-ROM intervention | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): Counseling | Intervention Type: OTHER; Name: CD-ROM intervention; Assigned to Arm(s): Counseling
C: Arm Label: Standard of Care (Control); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Patient-Guided; Type: EXPERIMENTAL; Interventions: Other: Patient-Guided | Arm Label: Educator-Guided; Type: EXPERIMENTAL; Interventions: Other: Patient-Guided, Other: Educator-Guided | Intervention Type: OTHER; Name: Patient-Guided; Assigned to Arm(s): Educator-Guided, Patient-Guided | Intervention Type: OTHER; Name: Educator-Guided; Assigned to Arm(s): Educator-Guided
D: Arm Label: FRAX + Decision Aid; Type: EXPERIMENTAL; Interventions: Behavioral: FRAX + Decision Aid | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: FRAX estimated fracture risk; Type: EXPERIMENTAL; Interventions: Behavioral: FRAX estimated fracture risk | Intervention Type: BEHAVIORAL; Name: FRAX + Decision Aid; Assigned to Arm(s): FRAX + Decision Aid | Intervention Type: BEHAVIORAL; Name: FRAX estimated fracture risk; Assigned to Arm(s): FRAX estimated fracture risk

Answer: D